9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Resveratrol-loaded polymeric micelles protect cells from Aβ-induced oxidative stress

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resveratrol has been reported to protect several types of cells against beta-amyloid peptide (Abeta) toxicity by scavenging reactive oxygen species (ROS) and inactivating caspase-3. However, other studies found that long-term treatment with resveratrol inhibited cells by inducing ROS generation and activating caspase-3. In the current report, a 48-h incubation of resveratrol at the concentrations of 5 and 10 microM significantly attenuated the viability of PC12 cells and a 12-h pre-incubation of resveratrol did not protect PC12 cells against Abeta exposure (even further inhibited PC12 cells at the concentrations of 10 microM) by acting as a pro-oxidant. Due to the lipophilicity of resveratrol, resveratrol-loaded polymeric micelles basing on amphiphilic block copolymer were developed. Then, the effects of resveratrol-loaded polymeric micelles on the viability and Abeta protection of PC12 cells were investigated. At the equivalent concentrations of 5 and 10 microM resveratrol, a 48-h incubation of resveratrol-loaded nanoparticles did not show toxicity to cells, while 12-h pre-incubation of resveratrol-loaded nanoparticles protected PC12 cells from Abeta-induced damage in a dose dependent manner (1-10 microM) by attenuating intracellular oxidative stress and caspase-3 activity. Further investigations are absolutely needed to evaluate the feasibility and advantages of in vivo applications of resveratrol-loaded nanoparticles.

          Related collections

          Author and article information

          Journal
          International Journal of Pharmaceutics
          International Journal of Pharmaceutics
          Elsevier BV
          03785173
          June 2009
          June 2009
          : 375
          : 1-2
          : 89-96
          Article
          10.1016/j.ijpharm.2009.03.021
          19481694
          89568cf4-4c1c-4668-bda1-4cde6ef5153e
          © 2009

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article